Abstract 16261: Risk of Stroke or Systemic Embolism After Transseptal Ablation in Patients With Implanted Cardiac Devices
Introduction: Mobile thrombi are commonly observed on endovascular leads at the time of catheter ablation. Transseptal puncture poses a risk of paradoxical embolism. We sought to examine the risk of stroke or systemic embolism after transseptal ablation in patients with and without cardiac implantable electronic devices (CIEDs).
Methods: Using a large, national administrative claims database we identified 31,720 patients who underwent a catheter ablation requiring transseptal puncture between 1/1/2004 and 9/30/2014. We created two propensity-matched cohorts, matching on age, gender, race, household income, region, Charlson index, CHADS-Vasc score, and year and indication for ablation (5,533 patients with CIEDs and 11,300 patients without devices). Incidence rates (events/100 patient-years) and propensity score-matched cox proportional hazards models (with 95% confidence intervals) were used to estimate risk of stroke, transient ischemic attack, or systemic embolism for patients with or without CIEDs. We also examined the impact of presence of a CIED and oral anticoagulation (OAC) use on risk of stroke or systemic embolism within the matched cohort. Average follow up was 2.1 years.
Results: The event rate was 1.5 per 100 person years in patients without device, and 1.9 per 100 person years in patients with device. Among patients not on OAC, presence of a cardiac device was associated with an increased risk of stroke or systemic embolism (HR 1.71 [1.24-2.35], P<0.01) whereas there was no association among patients treated with OAC (0.98 [0.75_1.28], p=ns) (Figure).
Conclusions: Cardiac devices are associated with an increased risk of stroke or systemic embolism after transseptal ablation, but this risk is attenuated with post ablation OAC use. Anticoagulation should be considered for all patients with CIEDs post transseptal ablation, regardless of the presence of another compelling indication for anticoagulation.
Author Disclosures: P. Noseworthy: None. M. Madhavan: None. C. DeSimone: Research Grant; Modest; NIH T32 Training Grant. Honoraria; Modest; Soraker - St Jude <10000. C. McLeod: None. L. Sangaralingham: None. S. Asirvatham: Honoraria; Modest; Abiomed, Atricure, Biotronik, Biosense Webster, Boston Scientific, Medtronic, Medtelligence, St. Jude, Sanofi-Aventis, Wolters Kluwer, Elsevier, Zoll. Consultant/Advisory Board; Modest; Atricure, Boston Scientific, Medtronic, Zoll. X. Yao: None.
- © 2015 by American Heart Association, Inc.